Refined the focus of the Phase 3 program to accelerate path to potential U.S. approval and commercial launch in the Company’s highest priority market Discontinued the ex-U.S.-based PROACT 2 trial and ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback